0001628280-26-015165
SEC filingContineum Therapeutics, Inc. (CTNM), a clinical-stage biopharmaceutical company, reported a net loss of $60.0M for FY 2025 ended December 31, 2025, up 42% from $42.3M in FY 2024, driven by increased R&D expenses of $51.5M (34% YoY growth) from PIPE-791 Phase 2 IPF trial startup and chronic pain study, plus higher G&A of $16.5M. No revenue was recognized, as the $50.0M J&J upfront from PIPE-307 license was recorded in 2023. Loss from operations widened to $68.1M from $50.9M, offset by $8.2M interest income. Balance sheet strengthened with $276.6M total assets, including $75.6M cash equivalents and $187.3M marketable securities; stockholders' equity rose to $261.0M. Cash used in operations was $55.3M, funded by $112.7M financing including $93.0M follow-on offering and $19.0M ATM sales. Net cash increase of $53.7M supports runway through at least 12 months. Focus remains on PIPE-791 Phase 2 IPF (data 2028) and chronic pain topline Q2 2026, with PIPE-307 partnered to J&J.
Contineum Therapeutics reported FY2025 net loss of $60.0M, a 42% increase from $42.3M in FY2024, primarily due to elevated operating expenses totaling $68.1M (up 34% YoY). R&D expenses rose to $51.5M from $38.4M, driven by PIPE-791 Phase 2 IPF trial initiation and chronic pain Phase 1b enrollment completion. G&A increased to $16.5M from $12.5M amid public company costs and headcount growth. No revenue recognized in FY2025 (vs none in FY2024; prior J&J upfront fully amortized). Other income netted $8.1M, mainly $8.2M interest income. Comprehensive loss was $59.8M after $189K unrealized gain on securities.
No product revenue in FY2025 or FY2024, as no products are approved. Revenue from J&J License Agreement ($50.0M upfront) was fully recognized in Q2 2023 upon license transfer. Eligible for up to $1.0B milestones and low-double to high-teen royalties on PIPE-307 net sales, but all constrained pending achievements. No segment revenue breakdown disclosed.
Pre-revenue clinical-stage biotech with no gross margins. Operating loss expanded to $68.1M (100% of expenses) from $50.9M. Loss from operations reflects 100% R&D/G&A spend. Stock-based compensation rose to $10.0M (15% of op ex) from $6.8M. Interest income provided partial offset at $8.2M (12% of op ex). Accumulated deficit grew to $177.4M from $117.4M.
Operating cash use $55.3M (vs $32.8M prior), reflecting trial ramp. Investing cash use $3.7M (net securities activity). Financing $112.7M: $93.0M follow-on, $19.0M ATM, $0.7M options/ESPP. Net cash increase $53.7M to $75.6M equivalents + $187.3M securities ($262.9M total). Total assets $276.6M (up from $212.8M); liabilities $15.7M stable; equity $261.0M bolstered by $112.3M stock issuance.
Cash runway extends at least 12 months post-filing. Priorities: PIPE-791 IPF Phase 2 topline June 2028, chronic pain Phase 1b Q2 2026; PIPE-307 with J&J (RRMS Phase 2 missed endpoints; MDD Phase 2 ongoing). Deferred PrMS/CTX-343 pending funding. Expects higher R&D as trials advance; may seek partnerships/financing. Risks include trial delays, funding needs, J&J discretion on PIPE-307.